WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Parabolic Drugs
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Business Insights
NAMSA | August 03, 2021
NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization. Third in an advancing series, this acquisition follows NAMSA’s purchase announcements of Syntactx and American Preclinical Services (APS) in early 2021. Clinlogix, founded in 1999, is well-recognized for providing compreh...
Precision Vaccinations | April 14, 2020
Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...
Xtalks | July 08, 2020
COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...
Can-Fite BioPharma Ltd. | May 17, 2022
Can-Fite BioPharma Ltd. a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced that its patent titled "An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation" has been granted by the Israel Patent Office. This patent has been issued in approximately 40 countries and territories including Japan, South Korea, Hong Kong, Mexico, and in the European Union. It addre...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE